Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations by Jean, Stephanie et al.
Oncotarget48577www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 30
Paclitaxel is necessary for improved survival in epithelial ovarian 
cancers with homologous recombination gene mutations
Stephanie Jean1, Jiaqi Li2, Dionyssios Katsaros3, Bradley Wubbenhorst4, Kara N. 
Maxwell5, Lauren Fishbein6, Michael W. McLane7, Chiara Benedetto3, Emilie Marion 
Canuto3, Nandita Mitra2, Lin Zhang7,8, Katherine L. Nathanson4,8,* and Janos L. 
Tanyi1,7,*
1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, Pennsylvania, USA
2 Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
Pennsylvania, USA
3 Department of Surgical Sciences, Gynecologic Oncology, Azienda Ospedaliero-Universitaria Città della Salute, Turin, Italy
4 Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University 
of Pennsylvania, Philadelphia, Pennsylvania, USA
5 Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, Pennsylvania, USA
6 Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, Pennsylvania, USA
7 Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
8 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
* These authors co-directed these studies
Correspondence to: Katherine L. Nathanson, email: knathans@upenn.edu
Keywords: ovarian cancer, massively parallel sequencing, clinical molecular genetics, homologous recombination, paclitaxel
Received: September 16, 2015 Accepted: April 29, 2016 Published: May 14, 2016
AbstrAct
PURPOSE: To investigate the impact of somatic mutations in homologous 
recombination (HR) genes on the chemotherapeutic response and survival of patients 
with epithelial ovarian cancer (EOC). 
EXPERIMENTAL DESIGN: We performed targeted massively parallel sequencing 
of tumor DNA from 158 patients with EOC. We associated adjuvant chemotherapy 
and clinical outcome with mutations in selected genes, focusing on those encoding 
HR proteins.
RESULTS: HR mutations were found in 47 (30%) tumors. We did not detect an 
overall survival (OS) difference in advanced stage patients whose tumors had HR 
mutations compared to those without (median OS of 49.6 months (95% CI 29.9-
57.7) vs. 43.3 months (95% CI 31.9-75.47), p = 0.87). However, when stratified 
by chemotherapy regimen, patients whose tumors had TP53 and HR mutations 
demonstrated a marked survival advantage when treated with platinum and paclitaxel 
vs. platinum +/- cyclophosphamide (median OS of 90 months (95% CI 50-NA) vs. 
29.5 months (95% CI 17.7-50.5), p = 0.0005). 
CONCLUSIONS: Previous studies demonstrating a survival advantage for EOC 
patients with somatic HR mutations have been conducted with almost universal use 
of both platinum and paclitaxel. Our study is the first to our knowledge to compare 
cohorts with somatic HR gene mutations treated with and without paclitaxel containing 
platinum regimens. The survival benefit attributed to the platinum sensitivity of HR 
deficient ovarian cancers may depend upon the combined use of paclitaxel.
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IntroductIon
Epithelial ovarian cancer (EOC) remains the 
most deadly gynecologic cancer in the United States, 
and the fifth leading cause of cancer deaths in women 
[1]. Although the vast majority of EOC cases are 
sporadic, up to 20% are associated with inherited 
cancer susceptibility syndromes, most due to germline 
mutations in the homologous recombination (HR) genes 
BRCA1 and BRCA2 (BRCA1/2) [2]. EOC patients with 
inherited mutations in BRCA1/2 have a longer survival 
than patients with sporadic disease, believed to be in 
part due to increased sensitivity of the BRCA1/2 tumors 
to platinum-based therapy and other agents such as 
pegylated liposomal doxorubicin [3, 4]. Several studies 
suggest that sporadic ovarian carcinomas with somatic 
mutations in BRCA1/2 also display differential response 
to platinum treatment with improved survival [5-7]. 
Given this differential response, there is ongoing interest 
in expanding on the original concept of phenotype 
“BRCAness” [8], and identifying sporadic ovarian cancers 
with defects in the HR pathway that may benefit from 
platinum and PARP-inhibitor therapy [9, 10].
TCGA data demonstrate that up to 50% of EOC 
cases have either germline or somatic defects in HR genes 
[6]. Platinum based chemotherapy was initiated in the 
mid 1980s and the high frequency of HR gene mutations 
may partially explain the improved treatment outcomes 
after initiation of this therapy [11, 12]. The combination 
of platinum with paclitaxel was established in the mid 
1990s as the most effective and durable treatment of EOC, 
and has remained the standard of care [13-16]. All recent 
studies examining genetic/genomic correlates of survival 
of EOC patients are comprised of patients treated with 
both adjuvant platinum and paclitaxel [3, 5, 7, 9]. 
We examined cohorts of patients treated with 
platinum before and after the establishment of combination 
therapy with paclitaxel as first-line therapy of EOC. Our 
goal was to determine if survival differed based on tumor 
mutations and chemotherapy regimen. Currently, emphasis 
on treatment response for EOC is placed on platinum 
sensitivity, which dictates management with second and 
third line therapy as well as clinical trial eligibility. We 
aimed to examine the response of EOC patients with 
somatic HR gene mutations and delineate the contribution 
of paclitaxel added to a platinum-based regimen. 
results
clinical cohort characteristics
After two samples were removed due to poor 
sequencing quality, the total cohort included 158 patients, 
of which 144 (91%) had available clinical data. Of the 144 
EOC patients, 91 had serous, 44 had endometrioid and 9 
had clear cell histology (Table 1). 
Forty-four of the 144 patients with clinical data 
had stage 1 or 2 disease, and the remaining 100 patients 
had stage 3-4 disease (70%). All patients who received 
adjuvant chemotherapy (n = 121) received a platinum 
based regimen. Of the advanced stage patients, thirty-
seven (37%) received first-line adjuvant treatment with 
platinum alone or with platinum plus cyclophosphamide. 
Fifty-seven patients (57%) received primary adjuvant 
treatment with platinum plus paclitaxel. Five patients (5%) 
received platinum, epirubicin, and cyclophosphamide for 
primary adjuvant therapy. An additional four patients 
(4%) received a combination of platinum, paclitaxel, 
and epirubicin for their primary adjuvant treatment. 
One patient with a synchronous endometrial cancer 
received primary adjuvant treatment with platinum plus 
doxorubicin.
somatic mutations and variants
From 158 tumors, we identified 224 deleterious 
variants in 34 genes, including 116 truncating mutations 
(50 nonsense, 66 frameshift) and 99 missense mutations. 
TP53 (n = 90) and BRCA1 (n = 26) mutations were the 
most frequent, followed by PTEN (n = 18), MSH6 (n = 14), 
NF1 (n = 12), RB1 (n = 9), BRCA2 (n = 8), and ATM (n = 
5) (Supplemental Table 1). Loss-of-function mutations in 
TP53 were found in 89 samples (56%). TP53 mutations 
were highly correlated with high-grade histology (Odds 
Ratio [OR] 6.5 with 95% CI: 2.57-16.4, p-value < 0.0001), 
including 53 (65.4%) high-grade serous, and 21 (24.7%) 
high-grade endometrioid tumors. Tumors with TP53 
mutations also included four (4.9%) low-grade serous and 
three (3.7%) low-grade endometrioid tumors. The majority 
of TP53 mutations were missense mutations within exons 
5-8, and previously described as pathogenic. We also 
identified 11 previously unreported frameshift mutations 
in TP53. 
Deleterious variants in genes encoding proteins of 
the HR pathway were detected in the ovarian cancers of 
47 patients (28%). Thirty mutations (63.8%) were found 
in high-grade serous; three (6.4%) in low-grade serous; 
10 (21.3%) in high-grade endometrioid; and four (8.5%) 
in low-grade endometrioid tumors. Mutations in the 
HR pathway were identified in 15 different genes: 26 
mutations in BRCA1 (58% of the HR gene variants), 8 
in BRCA2 (18%), 5 in ATM (11%), 3 in RBBP8 (7%), 3 
in PALB2 (7%), 2 in BRCC3 (4%), and 1 each in BAP1, 
BARD1, BLM, BRIP1, CHEK2, RAD50, RAD51C, 
RAD51D, and XRCC2 (2% each). Thirty-one of the 47 
patients with HR pathway mutations (66%) had co-
occurring TP53 mutations. 
We detected 26 loss-of-function BRCA1 mutations 
(6 nonsense, 12 frameshift, 7 missense, and 1 splicing). In 
addition, one tumor had two distinct frameshift insertions 
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in cis, (c.5077_5078insTCATT, c.5080_5081insC), located 
three base pairs apart. The combined insertions added six 
base pairs, returning the sequence in frame. The presence 
of a secondary mutation restoring a functional reading 
frame is a reported mechanism of resistance to platinum 
therapy [17] and observed in recurrent carcinomas after 
adjuvant chemotherapy with platinum-based regimens [18, 
19]. Interestingly, this patient had no known prior history 
of receiving chemotherapy or radiation. 
In 12 patients’ tumors, we detected 16 mutations 
in mismatch repair genes MSH2 and MSH6. Over half of 
these patients’ tumors (n = 7) had serous histology; three 
unique MSH6 variants were detected in a single tumor 
(p.F573fs, p.C694X p.T1085fs). In 12 patients’ tumors, 
we detected 18 mutations in PTEN. The majority of these 
tumors (n = 8) had serous histology. Two of the PTEN 
mutations were novel frameshift insertions, while the 
remaining mutations have been described previously. 
copy number analysis
The profile of copy number variation (CNV) 
resembled those previously described for high-grade 
serous ovarian cancers [20, 21]. Given our targeted design, 
we focused on gene-specific CNVs of tumor suppressor 
genes TP53, PTEN, RB1, and NF1, as well as genes 
involved in HR. We detected homozygous copy loss in 
one or more genes involved in HR in 23 (15%) tumors. 
Homozygous loss of BRCA1, CHEK2, and PALB2 often 
were found simultaneously, and homozygous loss of at 
least two of the three co-occurred in 17 tumors (Figure 1). 
We detected homozygous loss of PTEN in three tumors, 
MSH6 in nine tumors, PPM1D in 2 tumors, and TP53 
and SNAPC1 in one tumor each. We did not detect any 
instances of homozygous loss in RB1 or NF1.
table 1: clinical and mutational characteristics of subjects by chemotherapy regimen.
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survival and outcomes analysis
Increased overall survival (OS) was significantly 
related to younger age at time of surgery (p < 0.001) and 
earlier stage (p < 0.001). We analyzed whether patients 
with multiple somatic mutations (19 patients with at least 
three detected variants) demonstrated a survival difference, 
and although there was a trend towards worsened survival, 
it was not statistically significant (p = 0.298). 
We performed survival analyses of our advanced 
stage patients who received adjuvant chemotherapy (n = 
94). We did not find any difference in platinum sensitivity 
or overall survival in patients whose tumors had HR 
pathway mutations compared to those without such 
mutations (p = 0.84) (Figure 2A). Our patient population 
included 37 patients (39%) treated prior to the adoption 
of the combination of platinum and paclitaxel as the 
gold standard of first line adjuvant therapy; therefore, 
we investigated whether there was a difference between 
patients treated with platinum +/- cyclophosphamide, and 
platinum + paclitaxel. Our data confirm previous results 
that the patients who received platinum + paclitaxel had 
improved OS over patients who received platinum +/- 
cyclophosphamide [13, 14, 22] (median 57.7 months, 95% 
CI 33.8-102.2 vs. median 38.5 months, 95% CI 21-47.5, p 
= 0.019) (Figure 2B). 
To investigate the survival of patients whose tumors 
display a phenotype of “BRCAness,” we examined 
the subset of patients who had high-grade tumors with 
HR defects by analyzing patients with stage 3 and 4 
disease with tumors containing both HR and TP53 
mutations (which we term as having the “BRCAness” 
phenotype). Patients with tumors that contained HR 
and TP53 mutations who received platinum + paclitaxel 
demonstrated a markedly increased OS (median 90 
months, 95% CI 50-NA) compared to patients who 
received platinum +/- cyclophosphamide (median 
29.5 months, 95% CI 17.7-50.5, p = 0.0005) (Figure 
2C). In contrast, patients without the “BRCAness” 
phenotype who received platinum + paclitaxel had an OS 
(median 45.1 months, 95% CI 30.9-102.2) that was not 
significantly different than those who received platinum 
+/- cyclophosphamide (median 38.5 months, 95% CI 
17.1-52, p = 0.36) (Figure 2D). In addition, we found that 
patients with the “BRCAness” phenotype trended towards 
a decreased median OS than patients without “BRCAness” 
when treated with platinum +/- cyclophosphamide 
(median OS of 29.5 months vs. 38.5 months, respectively), 
though this was not statistically significant (p = 0.442). 
Our sample population was too small to perform 
multivariate analysis; however, the two subsets did not 
have any statistically significant differences in age, stage, 
or histology.
dIscussIon
EOC arising in germline BRCA1/2 mutation carriers 
is associated with increased chemosensitivity and a 
survival advantage [3, 23, 24]. Initial studies also suggest 
that somatic mutations in BRCA1/2 and other DNA 
repair genes confer similar benefits [6, 7, 9]. Sequencing 
52 genes in 158 EOC tumors, we detected mutations or 
deletions in 15 HR genes in the tumors of 45 patients 
(28%). More than half were found in BRCA1, followed by 
BRCA2 and ATM. These data are similar to Pennington, 
et al. who examined a series of 367 patients with EOC, 
fallopian tube cancer, or primary peritoneal cancer and 
found somatic HR mutations in seven genes in 8.7% of 
patients and germline mutations in 11 HR genes in 24% 
of patients [7]. In their study, HR gene mutations (both 
somatic and germline) were associated with improved 
platinum response and OS. We did not detect a survival 
Figure 1: somatic genomic landscape of epithelial ovarian cancer. This figure includes all genes with deleterious mutations that 
were detected in at least two distinct tumors. Mutation count, type, and associated clinical data are included, as well as instances of detected 
homozygous copy loss.
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advantage for patients with HR pathway mutations, even 
though all those treated with adjuvant chemotherapy 
received platinum containing agents. However, a critical 
difference between prior studies and the current study 
is that our cohort included some patients treated with 
platinum based regimens but not paclitaxel. Thus, we 
evaluated whether patients whose tumors had HR deficits 
might respond differentially to regimens that do or do not 
contain paclitaxel. 
In patients with high-grade tumors with HR 
and TP53 mutations (“BRCAness”), we found a 
striking disparity in survival depending on type of 
chemotherapy received. When treated with platinum 
+/- cyclophosphamide, patients whose tumors had 
the “BRCAness” phenotype had no difference in OS 
compared to patients whose tumors did not have the 
“BRCAness” phenotype. Conversely, when treated with 
platinum + paclitaxel, patients whose tumors had the 
“BRCAness” phenotype had significantly improved 
OS as compared to patients whose tumors did not. The 
marked median OS improvement of 60.5 months that 
we observed far exceeds the 10-14 month expected 
based on treatment regimen alone [13, 14]. These data 
suggest that somatic HR mutations may be associated 
with an improved response to paclitaxel. Recent studies 
demonstrating increased platinum sensitivity in HR 
pathway deficient sporadic EOC cancers have been done 
in tumors from patients treated with both platinum and 
taxane combination regimens as first line adjuvant therapy 
[6, 7, 9]. By utilizing a cohort of patients that includes 
those treated prior to use of taxanes, we found that the 
inclusion of paclitaxel likely plays an important role in 
survival in patients with HR-deficient tumors. 
The biological basis of platinum and PARP inhibitor 
sensitivity in HR-deficient ovarian tumors has been well 
explored in germline BRCA1/2 mutation carriers [25], 
and is thought to be due to accumulation of irreparable 
DNA damage and loss of functional double strand break 
Figure 2: overall survival (os) of advanced stage patients based on mutations and/or chemotherapy regimen (Platinum 
+ paclitaxel [PtX] or platinum +/- cyclophosphamide [c]). A. OS by the presence or absence of a homologous recombination 
(HR) gene mutation in the patient’s tumor. b. OS by chemotherapy regimen. c. OS by chemotherapy regimen in patients whose tumors 
exhibit the “BRCAness” phenotype (both a HR and TP53 mutation) or d. those without the “BRCAness” phenotype. 
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repair mechanisms, respectively, leading to cell and tumor 
death. However, there are only a few studies examining 
the effect of taxanes on ovarian cancers with HR deficits. 
One study examined the development of chemoresistance 
in ovarian cancer cell lines and found that cell lines with 
functional BRCA1 developed paclitaxel resistance more 
quickly than cell lines with non-functional BRCA1 (due 
to gene silencing by hypermethylation) [26]. Another 
study examined the ovarian cancer cell line SNU251, 
and found that a truncated and dysfunctional BRCA1 
protein impaired sub-nuclear protein assembly required 
for DNA damage repair, and subsequently led to increased 
sensitivity of the cells to taxol therapy [27]. Although 
there are a limited number of clinical studies examining 
taxane sensitivity in germline BRCA1/2 mutation carriers 
with EOC, several have demonstrated a synergy between 
platinum and taxanes. In a small study of recurrent 
platinum sensitive ovarian cancer patients, BRCA1/2 
mutation carriers demonstrated a significant response to 
repeat carboplatin with dose dense paclitaxel regimens, 
compared to sporadic patients, suggesting that this drug 
combination is particularly effective in BRCA1/2-related 
disease [28], and potentially by extension to HR deficient 
tumors. In addition, a study examining the role of taxane 
monotherapy in germline BRCA1/2 mutation carriers 
with relapsed ovarian cancer found a significant survival 
benefit in patients with initially platinum-sensitive disease 
compared to those with platinum-resistant disease [29]. 
Both the pre-clinical and clinical data support our finding 
that EOC tumors with BRCA1 (and other HR gene) 
mutations have an increased sensitivity to paclitaxel as 
compared to tumors without such mutations.
Recently, it has been hypothesized that the 
predominant cytotoxic mechanism of paclitaxel is due 
to chromosomal missegregation rather than strict mitotic 
arrest as traditionally believed [30]. Chromosomal 
missegregation causes genomic instability that leads 
to accelerated cell death. We postulate that tumors 
with deficient double strand break repair due to HR 
mutations are particularly susceptible to chromosomal 
missegregation, increasing their sensitivity to paclitaxel 
and contributing to the marked improvement in OS 
observed in our population. 
Our study has several limitations. We have a 
relatively small sample size for subgroup analysis. Our 
capture panel is targeted rather than whole-exome or 
whole-genome, which would limit potential novel gene 
findings. Additionally, our mutational profiling is based on 
somatic findings without germline comparison. Some of 
the mutations we detected may be unrecognized germline 
mutations; for example, two of our patients demonstrate 
a BRCA1 mutation recently described as a possible 
Northern Italian founder mutation [31], and one of the 
MSH6 mutations we detected in five different patients has 
been described in a family with Muir-Torre syndrome, a 
variant of Lynch syndrome [32] as well as a family with 
early-onset colorectal cancer [33]. Nevertheless, given the 
practice of tumor tissue sequencing without accompanying 
germline testing [34], we believe our findings are 
applicable in the clinical setting. We recognize that the 
rate of TP53 mutation in our high-grade serous tumor 
cohort does not reach the >95% seen in recent literature 
[6], even with rigorous pathology and sequencing quality 
control. In addition, there are histology differences in our 
two chemotherapy cohorts, amplified by small numbers 
of rare histology types. We believe that these limitations 
are remedied by the fact that our major analysis focuses 
strictly on tumors that exhibit both TP53 and HR gene 
mutations, capturing the “BRCAness” phenotype we 
aimed to study.
Our study is the first to our knowledge to 
demonstrate that EOC cancer patients with somatic 
HR gene mutations demonstrate no improvement in, 
and potentially worsened, survival than those without 
such mutations, unless they receive taxane therapy in 
addition to platinum adjuvant chemotherapy. Our long 
term follow-up of up to 18 years (median 57.7 months), 
as well as our unique subset of patients treated without 
a taxane chemotherapeutic agent allows us to highlight 
the importance of paclitaxel added to a platinum-based 
therapy for survival in patients with somatic HR deficits. 
Further study of the mechanism of taxane chemo-
responsiveness in somatic HR-pathway mutated EOC is 
warranted, and may uncover new targets for therapy and a 
better understanding of tumor progression and resistance 
in sporadic EOC. Although primary adjuvant treatment 
with platinum and taxanes is standard, subsequent lines 
of therapy after recurrence are not standardized and 
optimal regimens remain uncertain. Knowledge of the 
“BRCAness” phenotype of a sporadic EOC patient’s 
tumor may aid in selection of second, third, and further 
lines of treatment, and given our data, prioritizing use of 
taxanes in these situations should be considered. 
mAterIAls And methods
Tumor samples from patients diagnosed with 
primary epithelial ovarian carcinoma from December 
1991 - December 2005 at the University of Turin, in Turin, 
Italy were included in this analysis, which was performed 
with IRB approval. Patients with any grade or stage of 
pathology-confirmed serous, endometrioid, or clear cell 
ovarian carcinoma were eligible. All patients underwent 
primary cytoreductive surgery, from which research 
tumor specimens were obtained with informed consent. 
A segment of the tumor specimen was snap frozen for 
subsequent DNA extraction and subsequently stored at 
-80°C. Patients were followed from time of initial surgery 
to time of death or last follow-up, and clinical information 
on chemotherapy regimen, treatment response, recurrence, 
and survival were recorded. Patients treated with adjuvant 
chemotherapy received platinum with or without 
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cyclophosphamide, paclitaxel, and/or an anthracycline. 
Somatic mutation screening was performed using a 
custom designed targeted massively parallel sequencing 
protocol. Genomic DNA library construction was 
performed using TruSeq (Illumina, San Diego, CA). 
Genomic DNA was sheared with fragmentase (New 
England Biolabs, Ipswich, MA) to achieve fragments 
of 180-280 bp. DNA was end repaired and ligated 
with adaptor-embedded indexes. Then the DNA was 
purified and size-selected using 2% SizeSelect E-gels 
(Invitrogen, Eugene, OR) and PCR enriched. DNA 
quantity and quality were analyzed using the Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA). High quality 
samples were pooled and hybridized to a custom capture 
library using Agilent SureSelect kits. DNA quality, size, 
and concentration were assessed using the Qubit® 2.0 
fluorometer (Life Technologies, Carlsbad, CA) and the 
Bioanalyzer. Library captures were sequenced using the 
HiSeq 2000 (Illumina) at the University of Pennsylvania 
Next Generation Sequencing Core. 
Our custom capture panel included 52 genes, 
primarily tumor suppressor genes, involved in pathways 
implicated in ovarian and/or breast cancer susceptibility 
and tumorigenesis, such as HR, mismatch repair, or 
checkpoint inhibition. The HR pathway associated genes 
we assessed included ATM, BRCA1, BRCA2, BAP1, 
BARD1, BLM, BRCC3, BRIP1, CHEK2, PALB2, RAD50, 
RAD51C, RAD51D, RBBP8, XRCC2, and XRCC3. In 
addition, the following genes were also included on our 
panel: ATR, BABAM1, BRE, CDH1, CDK4, CDKN2A, 
ERCC2, FAM175A, FANCE, JARID2, KDM6A, KEAP1, 
MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, 
PALB2, PHF3, PMS1, PMS2, PPM1D, PTEN, RAD51A, 
RAD51B, RB1, SETD2, SIRT1, SNAPC1, STK11, TET2, 
TP53, TP53BP1, UIMC1, and WRN.
Alignment to human reference genome NCBI Build 
37 was performed with the Burrows-Wheeler Aligner 
[35] and reads were analyzed using the Genome Analysis 
Toolkit for variant calling [36]. ANNOVAR was used for 
variant annotation [37, 38]. Samples were removed due 
to poor sequencing quality if more than 10% of targets 
had 0% coverage, or if at least 10x coverage was achieved 
in less than 50% of targets. Variant identification and 
classification was performed using a strict filtering and 
analysis pipeline that has previously been described and 
validated [39, 40]. Locus-specific databases, ClinVar, 
dbSNP, and COSMIC were utilized to help identify 
suspected deleterious variants, and any missense variant 
calls that could not be confirmed in the literature were 
considered variants of undetermined significance (VUS) 
and excluded from analysis. Pindel [41] was utilized to 
detect large rearrangements or indels. 
Copy number analysis (CNA) was performed using 
ngCGH (next generation CGH) using germline DNA 
from a cohort of breast cancer patients as normal DNA 
for comparison which was matched to each EOC tumor 
specimen by mean target depth of coverage. CNA was 
visualized using Nexus Copy Number software version 7.5 
Discovery Edition (BioDiscovery Inc., Hawthorne, CA). 
Given the targeted gene design, CNA was performed on a 
gene-by-gene basis, and selected tumor suppressor genes 
were analyzed for homozygous copy loss.
statistical analysis
Overall survival was determined using Kaplan 
Meier analysis and Log-rank tests for significance. Cox 
proportional hazards models were used to adjust for age, 
stage, and histology. We focused on advanced stage (stages 
III-IV) patients given the marked survival difference in 
this population, and assessed survival differences due 
to mutation status and chemotherapy regimen using Chi 
square and Fisher’s Exact tests. All statistical analyses 
were performed using Stata Version 12 (College Station, 
TX) and R version 2.15.1 (Vienna, Austria). Statistical 
significance was set at alpha = 0.05 and all tests were 
2-tailed.
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